Lupin Secures Global Pact with Zentiva for Biosimilar Certolizumab; Bags $10 Mn Upfront

Mumbai, July 9, 2025 — Lupin Limited (NSE: LUPIN, BSE: 500257) has signed a definitive licensing and supply deal with European pharmaceutical major Zentiva Group to take its biosimilar Certolizumab Pegol to global markets. This is considered a key step forward in the company’s push to grow its biopharma footprint.

Key Partnership Highlights

Lupin will handle everything from development to manufacturing for Certolizumab Pegol, while Zentiva will take charge of getting the drug to patients across markets outside the US and Canada. The partnership plays to both companies’ strengths, Lupin’s expertise in biosimilar production and Zentiva’s deep regulatory experience and strong commercial presence across Europe and the CIS region.

Lupin will directly handle marketing in the USA, Canada, and other global territories outside Zentiva’s scope.

Financial Terms

Both companies will co-invest in product development and share profits from specified regions under the terms of the deal.

Product Overview: Certolizumab Pegol

Certolizumab Pegol is a recombinant, humanized antibody Fab’ fragment targeted against tumor necrosis factor alpha (TNFα) and is PEGylated for enhanced efficacy. It is used in the treatment of:

• Rheumatoid arthritis
• Psoriatic arthritis
• Non-radiographic axial spondyloarthritis
• Plaque psoriasis (moderate-to-severe)
• Crohn’s disease
• Polyarticular juvenile idiopathic arthritis

Management Commentary

Fabrice Egros, President of Corporate Development, Lupin, stated: “Our global development and commercialization partnership with Zentiva, with its pan-European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe. This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide.”

Strategic Outlook

This move strengthens Lupin’s footprint in the biosimilars segment and enhances its global relevance in immunology and chronic care therapies. The financial structure of the deal reflects Lupin’s capital-light approach to global expansion while ensuring accelerated market access across regulated markets.

Lupin Stock Performance

Lupin shares gained ₹1,912 on July 9, 2025, representing a 0.53% increase from the previous close. Lupin shares have gained 5.3% over the last year but have declined 19% year-to-date, experiencing a 4.14% dip during the last month.

About Lupin

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India. It operates in over 100 countries and specializes in branded and generic formulations, complex generics, biotechnology products, and APIs. The company has 15 manufacturing sites, 7 R&D centers, and over 23,000 employees worldwide. It maintains leadership across therapeutic areas such as respiratory, cardiovascular, diabetes, anti-infectives, gastrointestinal, CNS, and women’s health.

REF:https://www.bseindia.com/xml-data/corpfiling/AttachLive/d3ee6e95-f2ac-42a8-9cb2-adeaaebc3c1b.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations